Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL5586520 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL3487131 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL27769534 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL28106594 | 0.95 | PTGS1 (0.47) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL28213703 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL20678167 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL16637167 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL1507561 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL16970950 | 0.93 | CYP1A2 (0.50) | PTGS1SLC7A11OTCDDAH1NOS2 | |
| Arginine SCHEMBL16970951 | 0.93 | CYP1A2 (0.50) | PTGS1SLC7A11OTCDDAH1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113398280-A | Ligand-bound copper clusters, compatibility of ligand-bound copper clusters and application of ligand-bound copper clusters in treatment of liver cirrhosis | 武汉广行科学研究有限公司 | 2021-09-17 | — | — | CN | claimed |
| US-4996292-A | Self-sealing artificial skin comprising copoly-alpha-amino acid | FOX SIDNEY W (US) | 1991-02-26 | — | — | US | claimed |
| US-20240132599-A1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | ADAPTATE BIOTHERAPEUTICS LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20230391830-A1 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS | VERIMMUNE INC. | 2023-12-07 | — | — | US | disclosed |
| US-11560408-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | VERIMMUNE INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115491418-A | Second-generation sequencing panel of target genes with congenital incomplete lens dislocation and sequencing method | 复旦大学附属眼耳鼻喉科医院 | 2022-12-20 | — | — | CN | disclosed |
| EP-3902527-A1 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS | VerImmune Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200291072-A1 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS | VERIMMUNE INC. | 2020-09-17 | — | — | US | disclosed |
| CN-109134371-B | Fluorescence ratio probe, synthetic method thereof and application of fluorescence ratio probe in detecting intracellular lysosome formaldehyde | 东北大学 | 2020-07-10 | — | — | CN | disclosed |
| WO-2020139978-A1 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS | VERIMMUNE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
| CN-103517987-B | Change type lipase and manufacture method thereof and use the reaction of this enzyme | 宇部兴产株式会社 | 2016-10-12 | — | — | CN | disclosed |
| US-7223726-B2 | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060233839-A1 | Novel compounds | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2006-10-19 | — | — | US | disclosed |
| US-6825328-B1 | Lafora's disease gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| US-20040234538-A1 | Derp1 and proderp1 allergen derivatives | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2004-11-25 | — | — | US | disclosed |
| US-20030181372-A1 | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-25 | — | — | US | disclosed |
| EP-0975798-A1 | METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 | YALE UNIVERSITY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998040516-A1 | METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 | YALE UNIVERSITY (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0504234-A1 | ANTIBODIES PREVENTING INTERACTION BETWEEN A FRAGMENT Fc OF AN IMMUNOGLOBULIN AND ITS RECEIVER, AND THERAPEUTIC USE, PARTICULARILY IN TREATING AFFECTIONS LINKED TO THE HIV VIRUS | JACQUILLAT, Annie (représentante légale de l'inventeur décédé) (FR) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991008301-A1 | PROTEINS PREVENTING INTERACTION BETWEEN A FRAGMENT Fc OF AN IMMUNOGLOBULIN AND ITS RECEIVER, AND THERAPEUTIC USE, PARTICULARILY IN TREATING AFFECTIONS LINKED TO THE HIV VIRUS | UNIVERSITE PIERRE ET MARIE CURIE (FR) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060233839-A1 | Novel compounds | HRH1, HRH4, DERL1 | PTGS1 713/4885SLC7A11 4758/4885OTC 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.